On May 8, 2018, Takeda Pharmaceutical (Takeda), the Japanese-based global pharmaceutical company, acquired Shire, the Irish global biopharmaceutical firm, for a total of $83 billion. Over the past few years, Takeda has been on a transformation journey to becoming best-in-class pharmaceutical company that provides innovative medicine and transformative care to patients around the world. Nomura’s long standing relationship with Takeda and the capability to navigate through complex cross border transactions, won a role as joint financial advisor to Takeda’s strategic move. The transaction is also particularly notable because it represents the largest M&A deal in Japan, and the second largest UK deal ever.
This transformational transaction, brings together Takeda and Shire’s complementary positions in gastroenterology and neuroscience, and further provides leading positions in rare diseases and plasma-derived therapies. As Takeda continues their global expansion, Nomura is constantly on the lookout for best-practices and bespoke solutions to cater changing client needs.
Hajime Higuchi, Head of M and A, Asia ex-Japan
Apoorva Shah, Co-Head of M and A, Asia ex-Japan
